Changhong Xu

Changhong Xu

Auto-generated profile, based on publicly available information

Changhong Xu

Department of Urology The Second Hospital & Clinical Medical School, Lanzhou University Lanzhou City Gansu Province China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2025 in Phytomedicine
Verified
Journal Article
Closed access
CXChanghong Xu
Changhong Xu
HWHuaBin Wang
HuaBin Wang
HWHailong Wang
Hailong Wang
JMJiangwei Man
Jiangwei Man
YDYun Deng
Yun Deng
LYLi Yang
Li Yang

24 July 2026 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JMJiangwei Man
Jiangwei Man
KWKangyu Wang
Kangyu Wang
YZYalong Zhang
Yalong Zhang
HWHao Wang
Hao Wang
CXChanghong Xu
Changhong Xu
LYLi Yang
Li Yang
TRIM47 is an emerging E3 ubiquitin ligase of the tripartite motif family that has been increasingly implicated in inflammation, tissue injury, fibrosis, and cancer. Rather than acting as a disease‐specific factor, TRIM47 appears to function as a context‐dependent organizer of ubiquitin signaling, in which substrate selection and ubiquitin‐chain topology shape distinct pathological outputs. Through K48‐linked ubiquitination, TRIM47 promotes degradation of inhibitory or protective proteins, including CYLD, SIRT1, PPM1A, FBP1, CDO1, p53, Smad4, and XAF1, whereas through K63‐linked ubiquitination it enhances signaling activity of mediators such as NEMO and PARP1. These substrate‐ and chain‐dependent actions converge on a limited set of recurrent mechanisms, including inflammatory amplification, profibrotic remodeling, metabolic reprogramming, ferroptosis resistance, apoptosis escape, and DNA repair rewiring. This framework helps explain the repeated involvement of TRIM47 across innate immune dysregulation, organ injury, fibrogenesis, tumor progression, and treatment response. Notably, TRIM47 may also act as a double‐edged regulator of therapy, promoting resistance to platinum‐, taxane‐, and endocrine‐based treatments while potentially increasing vulnerability to PARP inhibition in selected homologous recombination‐deficient settings. Although these observations support TRIM47 as a promising biomarker and therapeutic target, major gaps remain, including incomplete substrate and ubiquitin‐site mapping, limited cell type‐specific in vivo validation, insufficient structural and interactome data, and the lack of TRIM47‐selective inhibitors. A mechanism‐centered understanding of TRIM47 will be essential for improving disease stratification and developing rational TRIM47‐directed therapies.